OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone1-855-961-9420
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$61.27 million
Profitability
Miscellaneous
Employees615
Next Earnings Date4/20/2020 (Estimated)
OptionableNot Optionable
OrganiGram (NASDAQ:OGI) Frequently Asked Questions
What is OrganiGram's stock symbol?
OrganiGram trades on the NASDAQ under the ticker symbol "OGI."
How were OrganiGram's earnings last quarter?
OrganiGram Holdings Inc (NASDAQ:OGI) released its quarterly earnings data on Monday, July, 15th. The company reported ($0.07) EPS for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.09. The firm earned $30.36 million during the quarter, compared to the consensus estimate of $30.81 million. OrganiGram had a negative net margin of 42.78% and a negative return on equity of 6.13%. The business's quarterly revenue was up 782.6% on a year-over-year basis. View OrganiGram's Earnings History.
When is OrganiGram's next earnings date?
What price target have analysts set for OGI?
10 analysts have issued 1 year target prices for OrganiGram's stock. Their forecasts range from $8.20 to $17.10. On average, they expect OrganiGram's share price to reach $10.96 in the next year. This suggests a possible upside of 398.2% from the stock's current price. View Analyst Price Targets for OrganiGram.
What is the consensus analysts' recommendation for OrganiGram?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OrganiGram.
Has OrganiGram been receiving favorable news coverage?
News headlines about OGI stock have trended very negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OrganiGram earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for OrganiGram.
Are investors shorting OrganiGram?
OrganiGram saw a drop in short interest in February. As of February 14th, there was short interest totalling 10,410,000 shares, a drop of 9.4% from the January 30th total of 11,490,000 shares. Based on an average daily volume of 3,950,000 shares, the short-interest ratio is currently 2.6 days. Approximately 6.7% of the company's stock are sold short. View OrganiGram's Current Options Chain.
Who are some of OrganiGram's key competitors?
Some companies that are related to OrganiGram include Constellation Pharmaceuticals (CNST), Esperion Therapeutics (ESPR), Innoviva (INVA), Theravance Biopharma (TBPH), Dicerna Pharmaceuticals (DRNA), Revance Therapeutics (RVNC), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), ZEALAND PHARMA/S (ZEAL), TG Therapeutics (TGTX), Nabriva Therapeutics (NBRV), Intra-Cellular Therapies (ITCI), Amneal Pharmaceuticals (AMRX), Y-mAbs Therapeutics (YMAB) and Akebia Therapeutics (AKBA).
What other stocks do shareholders of OrganiGram own?
Who are OrganiGram's key executives?
OrganiGram's management team includes the folowing people:
- Mr. Greg Engel, CEO & Director (Age 54)
- Mr. Paolo De Luca C.A., C.F.A, Chief Financial Officer (Age 46)
- Mr. Jeff Purcell, VP - Operations
- Mr. Timothy Emberg, Sr. VP of Sales & Commercial Operations
- Mr. Peter R. Hanson, Director of Fin.
Who are OrganiGram's major shareholders?
OrganiGram's stock is owned by many different of institutional and retail investors. Top institutional investors include FIL Ltd (1.01%), AdvisorShares Investments LLC (0.49%), Ancora Advisors LLC (0.21%), Swiss National Bank (0.18%), Virtu Financial LLC (0.13%) and CIBC World Markets Inc. (0.12%).
Which institutional investors are selling OrganiGram stock?
OGI stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Goldman Sachs Group Inc., Bank of America Corp DE, Jane Street Group LLC, Bank of Montreal Can, Rothschild Investment Corp IL, Ingalls & Snyder LLC and Cambridge Investment Research Advisors Inc..
Which institutional investors are buying OrganiGram stock?
OGI stock was purchased by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Swiss National Bank, Virtu Financial LLC, TD Asset Management Inc., Credit Suisse AG, Formidable Asset Management LLC, CIBC World Markets Inc. and Toronto Dominion Bank.
How do I buy shares of OrganiGram?
Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OrganiGram's stock price today?
One share of OGI stock can currently be purchased for approximately $2.20.
How big of a company is OrganiGram?
OrganiGram has a market capitalization of $359.44 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe.View Additional Information About OrganiGram.
What is OrganiGram's official website?
How can I contact OrganiGram?
OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.
MarketBeat Community Rating for OrganiGram (NASDAQ OGI)
MarketBeat's community ratings are surveys of what our community members think about OrganiGram and other stocks. Vote "Outperform" if you believe OGI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGI will underperform the S&P 500 over the long term. You may vote once every thirty days.
